Open-Label, Single- and Multiple-Dose Pharmacokinetic Study of Diazoxide Choline
Primary Purpose
Hypertriglyceridemia
Status
Withdrawn
Phase
Phase 1
Locations
Study Type
Interventional
Intervention
Diazoxide choline
Diazoxide choline high dose
Sponsored by
About this trial
This is an interventional treatment trial for Hypertriglyceridemia
Eligibility Criteria
Inclusion Criteria:
- Signed informed consent
- Healthy adults
- Fasting glucose ≤ 125 mg/dL and HbA1C ≤ 6.5
- Fasting triglyceride ≥150 mg/dL and ≤ 500 mg/dL
Exclusion Criteria:
- Known CAD, DM, uncontrolled HTN
- Pregnancy or unable to complaint with the birth control method required
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Experimental
Arm Label
Sequence 1
Sequence 2
Arm Description
Single dose of low dose DCCR followed by a 14 day washout, then re-randomized to either low or high multiple dose DCCR
Single dose of high dose DCCR followed by a 14 day washout, then re-randomized to either low or high multiple dose DCCR
Outcomes
Primary Outcome Measures
Compare the single-dose and steady-state, fed and fasting PK profiles of two dose levels of diazoxide administered as DCCR
Secondary Outcome Measures
Assess the impact of dosing in the absence of food on the steady-state pharmacokinetic profiles of two dose levels of diazoxide administered orally as DCCR under fed conditions
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT00901823
Brief Title
Open-Label, Single- and Multiple-Dose Pharmacokinetic Study of Diazoxide Choline
Official Title
A Randomized, Open-Label, Single- and Multiple-Dose, Four-Way Parallel Study Comparing the Fed and Fasted Pharmacokinetics of Two Dose Levels of Diazoxide Choline Controlled-Release Tablet (DCCR) in Healthy VolunteersVOLUNTEERS
Study Type
Interventional
2. Study Status
Record Verification Date
August 2016
Overall Recruitment Status
Withdrawn
Why Stopped
Did not support the planned development of DCCR in the new indication
Study Start Date
March 2011 (undefined)
Primary Completion Date
March 2011 (Anticipated)
Study Completion Date
March 2011 (Anticipated)
3. Sponsor/Collaborators
Name of the Sponsor
Essentialis, Inc.
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
This is a single-center, randomized, open-label, single- and multiple-dose, five-treatment, two-period, four-way parallel study comparing the pharmacokinetics (PK) of Diazoxide Choline Controlled-Release Tablet (DCCR) administered orally under fed and fasting conditions at two dose levels.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertriglyceridemia
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Crossover Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
0 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Sequence 1
Arm Type
Experimental
Arm Description
Single dose of low dose DCCR followed by a 14 day washout, then re-randomized to either low or high multiple dose DCCR
Arm Title
Sequence 2
Arm Type
Experimental
Arm Description
Single dose of high dose DCCR followed by a 14 day washout, then re-randomized to either low or high multiple dose DCCR
Intervention Type
Drug
Intervention Name(s)
Diazoxide choline
Intervention Description
A single dose low dose DCCR then re-randomized to either multiple dose low dose DCCR or high dose DCCR
Intervention Type
Drug
Intervention Name(s)
Diazoxide choline high dose
Intervention Description
A single dose high dose DCCR then re-randomized to either low or high multiple doses of DCCR
Primary Outcome Measure Information:
Title
Compare the single-dose and steady-state, fed and fasting PK profiles of two dose levels of diazoxide administered as DCCR
Time Frame
35 days
Secondary Outcome Measure Information:
Title
Assess the impact of dosing in the absence of food on the steady-state pharmacokinetic profiles of two dose levels of diazoxide administered orally as DCCR under fed conditions
Time Frame
35 days
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Signed informed consent
Healthy adults
Fasting glucose ≤ 125 mg/dL and HbA1C ≤ 6.5
Fasting triglyceride ≥150 mg/dL and ≤ 500 mg/dL
Exclusion Criteria:
Known CAD, DM, uncontrolled HTN
Pregnancy or unable to complaint with the birth control method required
12. IPD Sharing Statement
Learn more about this trial
Open-Label, Single- and Multiple-Dose Pharmacokinetic Study of Diazoxide Choline
We'll reach out to this number within 24 hrs